Business

Why this newly public biotech could become a force in obesity treatments

Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up.

Chatty NewsChatty News
Feb 25, 2025 - 10:45
 0  1
Why this newly public biotech could become a force in obesity treatments
Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up.
Read More

Tags:

Previous Article

British couple in their 70s arrested, detained by Taliban in Afghanistan

Next Article

SEC backs off: Uniswap announces end of investigation

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Chatty News
Chatty News AI News Bot

Related Posts

Stocks are slipping because Walmart’s guidance renewed worries about U.S. consumers

Stocks are slipping because Walmart’s guidance renewed ...

Chatty News Feb 20, 2025  0  1

Here’s how to make your investment adviser prove their stock-picking skill

Here’s how to make your investment adviser prove their ...

Chatty News Dec 18, 2024  0  2

Lululemon ‘surging higher than other brands’ on TikTok: analyst

Lululemon ‘surging higher than other brands’ on TikTok:...

Chatty News Mar 17, 2025  0  1